Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel

NCT06947668 is registered in ClinicalTrials.gov with University of Erlangen-Nürnberg Medical School as lead sponsor.

NCT NCT06947668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06947668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel
Lead sponsor
University of Erlangen-Nürnberg Medical School
Phase
Observational
Overall status
Recruiting
Start date
May 1, 2025
Completion date
December 31, 2030
Enrollment
250 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

larynx squamous cell carcinoma, oral cavity squamous cell carcinoma, squamous cell carcinoma of oropharynx, squamous cell carcinoma of the hypopharynx